This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
CVS Health (CVS) Q4 Earnings to Gain From COVID Vaccine Sales
by Zacks Equity Research
CVS Health (CVS) is expected to have seen a significant part of its specialty orders being placed digitally through Q4 months, with growth drivers being COVID testing, vaccines and omni-channel.
Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results are likely to reflect solid performance in the Pharmaceutical segment.
Diagnostics Sales to Drive Hologic's (HOLX) Q1 Earnings
by Zacks Equity Research
Strength in the Diagnostics division is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q1 sales.
Stryker (SYK) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Despite pandemic-led disruptions, Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments.
McKesson (MCK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) struggles to sustain the recovery trend in the second half of 2021.
Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Diagnostics and Breast Health businesses is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.
Abiomed (ABMD) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q3 sales.
What's in Store for Quest Diagnostics (DGX) in Q4 Earnings?
by Zacks Equity Research
In Q4, Quest Diagnostics' (DGX) non-COVID base business might have registered a year-over-year sales rebound.
AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal first-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
CONMED's (CNMD) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
CONMED's (CNMD) fourth-quarter earnings reflect strong segmental performance.
Align Technology (ALGN) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Robust scanner shipments and an increase in Invisalign volumes within the teen segment are expected to have contributed to Align Technology's (ALGN) Q4 performance.
IDEXX (IDXX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Strong organic recurring revenue growth in the CAG diagnostics business and rise in new instrument placements are likely to have contributed to IDEXX's (IDXX) Q4 revenues.
Here's Why You Should Invest in Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein's (HSIC) strong segmental performance and raised 2021 EPS guidance.
Edwards Lifesciences (EW) Q4 Earnings Fall Shy of Estimates
by Zacks Equity Research
Strong sales growth across all four product groups along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) fourth-quarter revenues.
Abbott's (ABT) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Abbott's (ABT) COVID-19 testing-related sales in Q4 increased on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.
Here's Why You Should Add Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics' (DGX) improvement in base business and raised 2021 outlook.
PerkinElmer (PKI) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results are likely to reflect strong performance at the Diagnostics segment.
Rise in COVID Tests to Boost Thermo Fisher (TMO) Q4 Earnings
by Zacks Equity Research
With the emergence of the Omicron variant through the Q4 months globally, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered strong top-line contributions.
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Biologics segment is likely to have maintained its impressive performance over the past few months, thereby aiding Q2 results.
SmileDirectClub (SDC) Moves up on New Strategic Actions
by Zacks Equity Research
SmileDirectClub's (SDC) new strategic actions are focused on supporting the key growth initiatives that will generate the highest return on investment.
Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) fourth-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Here's Why You Should Add LabCorp (LH) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) backed by increased COVID-19 testing demand and development in high-growth areas.
Intuitive Surgical (ISRG) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter results reflect strong segmental performance.